Korro Bio, Inc. (KRRO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 20M 40M 60M Q2 '20: 44.7M Q3 '20: 31.7M Q4 '20: 37M Q1 '21: 34.4M Q2 '21: 35.3M Q3 '21: 24M Q4 '21: 14.1M Q1 '22: 9.4M Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q4 '24: 2.3M Q1 '25: 4.8M Q2 '25: 6.3M Q3 '25: 7.4M Q4 '25: 6.4M Q1 '26: 3.8M Q2 '26: 2.4M Q4 '20 Q3 '21 Q2 '22 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -72.9M Q4 '21: -84M Q1 '22: -87.1M Q2 '22: -90.9M Q3 '22: -86.2M Q4 '22: -59M Q1 '23: -55.8M Q2 '23: -53M Q3 '23: -51.8M Q4 '23: -84.5M Q1 '24: -85.9M Q2 '24: -91.6M Q3 '24: -95.8M Q4 '24: -91.9M Q1 '25: -95.5M Q2 '25: -98.6M Q3 '25: -94.5M Q4 '25: -121.9M Q1 '26: -117.3M Q2 '26: -110.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -73.4M Q4 '21: -84.7M Q1 '22: -87.7M Q2 '22: -91.3M Q3 '22: -85.7M Q4 '22: -58M Q1 '23: -54.3M Q2 '23: -50.6M Q3 '23: -49.6M Q4 '23: -81.2M Q1 '24: -81.1M Q2 '24: -85.3M Q3 '24: -87.8M Q4 '24: -83.6M Q1 '25: -87.4M Q2 '25: -91.4M Q3 '25: -88.4M Q4 '25: -117.3M Q1 '26: -113.5M Q2 '26: -106.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -73M Q4 '21: -76.1M Q1 '22: -67.9M Q2 '22: -63.7M Q3 '22: -60.5M Q4 '22: -53.6M Q1 '23: -56M Q2 '23: -57.2M Q3 '23: -57.2M Q4 '23: -67.3M Q1 '24: -69.5M Q2 '24: -69.4M Q3 '24: -73.7M Q4 '24: -60.1M Q1 '25: -62.6M Q2 '25: -67.3M Q3 '25: -68.4M Q4 '25: -78.6M Q1 '26: -70.2M Q2 '26: -67.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -80.3M Q4 '21: -79M Q1 '22: -70.3M Q2 '22: -64.1M Q3 '22: -60.6M Q4 '22: -58.8M Q1 '23: -62.6M Q2 '23: -68.3M Q3 '23: -68.5M Q4 '23: -75.1M Q1 '24: -81.4M Q2 '24: -82.8M Q3 '24: -91.8M Q4 '24: -78M Q1 '25: -75M Q2 '25: -73.9M Q3 '25: -70.2M Q4 '25: -79.1M Q1 '26: -70.6M Q2 '26: -68.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '22: 35.2M Q1 '23: 271.5K Q2 '23: 276.5K Q3 '23: 284.2K Q1 '24: 8M Q2 '24: 9M Q3 '24: 9.3M Q1 '25: 9.4M Q2 '25: 9.4M Q3 '25: 9.4M Q1 '26: 11.6M Q2 '26: 17.6M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-450.00 -300.00 -150.00 0.00 150.00 300.00 450.00 Q3 '21: -2.15 Q4 '21: -2.48 Q1 '22: -2.55 Q2 '22: -2.64 Q3 '22: -2.46 Q4 '22: -227.42 Q1 '23: -298.95 Q2 '23: -362.17 Q3 '23: -426.70 Q4 '23: -53.08 Q1 '24: 16.68 Q2 '24: 78.08 Q3 '24: 140.90 Q4 '24: -9.39 Q1 '25: -9.44 Q2 '25: -9.75 Q3 '25: -9.41 Q4 '25: -12.47 Q1 '26: -11.67 Q2 '26: -10.00 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.